FDA Approves Bristol Myers' Breyanzi (Liso-Cel) for Relapsed Mantle Cell Lymphoma, Third Approval This Year

May 30, 2024, 07:25 PM

The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Breyanzi, also known as Liso-Cel, a CAR T cell therapy, for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) after two lines of therapy. This approval, announced on Thursday, marks the third time this year that the FDA has expanded the use of Breyanzi for treating aggressive and rare types of blood cancer.